The Brazilian Clinical Protocol and Therapeutic Guidelines (in Portuguese, PCDT), which regulates the antisense oligonucleotide treatment for SMA type I, already includes pre-symptomatic SMA patients but with a familial history of SMA, genetic diagnosis, and up to three copies of SMN2 (available online: http://conitec.gov.br/images/Relatorios/2019/Relatorio_PCDT_AME.pdf (accessed on 12 March 2021)). Here, SMN2 is linked to spinal muscular atrophy, type 1.